学术探索
学术期刊
新闻热点
数据分析
智能评审

Mechanisms by which thiazolidinediones enhance insulin action

被引：83
作者：
Reginato, MJ
Lazar, MA
机构：
[1] Univ Penn, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Penn Diabet Ctr, Philadelphia, PA 19104 USA
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 1999年 / 10卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/S1043-2760(98)00110-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Thiazolidinediones (TZDs) are an exciting new class of insulin-sensitizing drugs being used currently for the treatment of non-insulin-dependent diabetes mellitus. The molecular target of these compounds is thought to be the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPAR gamma). PPAR gamma is expressed predominantly in adipose tissue, yet a major site of TZD-responsive glucose disposal is skeletal muscle. Potential explanations for this paradox are discussed in this review.
引用
收藏
页码：9 / 13
页数：5
相关论文
共 72 条
  • [1] Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
    Adams, M
    Reginato, MJ
    Shao, DL
    Lazar, MA
    Chatterjee, VK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) : 5128 - 5132
  • [2] Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice
    Berger, J
    Bailey, P
    Biswas, C
    Cullinan, CA
    Doebber, TW
    Hayes, NS
    Saperstein, R
    Smith, RG
    Leibowitz, MD
    [J]. ENDOCRINOLOGY, 1996, 137 (10) : 4189 - 4195
  • [3] BODEN G, 1997, DIABETES, V46, P1
  • [4] Troglitazone action is independent of adipose tissue
    Burant, CF
    Sreenan, S
    Hirano, KI
    Tai, TAC
    Lohmiller, J
    Lukens, J
    Davidson, NO
    Ross, S
    Graves, RA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) : 2900 - 2908
  • [5] CAMP HS, 1997, J BIOL CHEM, V272, P13452
  • [6] PEROXISOME PROLIFERATOR AND RETINOID SIGNALING PATHWAYS COREGULATE PREADIPOCYTE PHENOTYPE AND SURVIVAL
    CHAWLA, A
    LAZAR, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (05) : 1786 - 1790
  • [7] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)-GAMMA - ADIPOSE-PREDOMINANT EXPRESSION AND INDUCTION EARLY IN ADIPOCYTE DIFFERENTIATION
    CHAWLA, A
    SCHWARZ, EJ
    DIMACULANGAN, DD
    LAZAR, MA
    [J]. ENDOCRINOLOGY, 1994, 135 (02) : 798 - 800
  • [8] Serum immunoreactive leptin concentrations in normal-weight and obese humans
    Considine, RV
    Sinha, MK
    Heiman, ML
    Kriauciunas, A
    Stephens, TW
    Nyce, MR
    Ohannesian, JP
    Marco, CC
    McKee, LJ
    Bauer, TL
    Caro, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 292 - 295
  • [9] Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma
    DeVos, P
    Lefebvre, AM
    Miller, SG
    GuerreMillo, M
    Wong, K
    Saladin, R
    Hamann, LG
    Staels, B
    Briggs, MR
    Auwerx, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) : 1004 - 1009
  • [10] The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers
    DuBois, RN
    Gupta, R
    Brockman, J
    Reddy, BS
    Krakow, SL
    Lazar, MA
    [J]. CARCINOGENESIS, 1998, 19 (01) : 49 - 53
12345678